Literature DB >> 12667566

Comparison of arrhythmia recurrence in patients presenting with ventricular fibrillation versus ventricular tachycardia in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial.

Merritt H Raitt1, Richard C Klein, D George Wyse, Bruce L Wilkoff, Karen Beckman, Andrew E Epstein, James Coromilas, Peter L Friedman, James Martins, Robert B Ledingham, H Leon Greene.   

Abstract

Because many episodes of ventricular fibrillation (VF) are believed to be triggered by ventricular tachycardia (VT), patients who present with VT or VF are usually grouped together in discussions of natural history and treatment. However, there are significant differences in the clinical profiles of these 2 patient groups, and some studies have suggested differences in their response to therapy. We examined arrhythmias occurring spontaneously in 449 patients assigned to implantable cardioverter-defibrillator (ICD) therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial to determine whether patients who receive an ICD after VT have arrhythmias during follow-up that are different from patients who present with VF. ICD printouts were analyzed both by a committee blinded to the patients' original presenting arrhythmia and by the local investigator. During 31 +/- 14 months of follow-up, 2,673 therapies were reported. Patients who were enrolled in the AVID trial after an episode of VT were more likely to have an episode of VT (73.5% vs 30.1%, p <0.001), and were less likely to have an episode of VF (18.3% vs 28.0%, p = 0.013) than patients enrolled after an episode of VF. Adjustment for differences in ejection fraction, previous infarction, and beta-blocker and antiarrhythmic therapy did not appreciably change the results. Ventricular arrhythmia recurrence during follow-up is different in patients who originally present with VT than in those who originally present with VF. These findings suggest there are important differences in the electrophysiologic characteristics of these 2 patient populations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12667566     DOI: 10.1016/s0002-9149(03)00015-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Pan-Asia United States PrEvention of Sudden Cardiac Death Catheter Ablation Trial (PAUSE-SCD): rationale and study design.

Authors:  Minglong Chen; Shulin Wu; Yan Yao; Jian Jiang; Chenyang Jiang; Yumei Xue; Xianzhang Zhan; Hongde Hu; Guosheng Fu; Kai Gu; Hailei Liu; Ligang Ding; Ruhong Jiang; Fa-Po Chung; Yenn-Jiang Lin; Yuichi Hori; Yuki Komatsu; Akiko Ueda; Kyoko Soejima; Young Hoon Kim; Akihiko Nogami; Shiro Nakahara; Shih-Ann Chen; Roderick Tung
Journal:  J Interv Card Electrophysiol       Date:  2019-03-19       Impact factor: 1.900

2.  Analysis of implantable cardioverter defibrillator signals for non conventional cardiac electrical activity characterization.

Authors:  Aldo Casaleggio; Paolo Rossi; Andrea Faini; Tiziana Guidotto; Vincenzo Malavasi; Giacomo Musso; Giuseppe Sartori
Journal:  Med Biol Eng Comput       Date:  2006-03       Impact factor: 2.602

3.  Electrical storms in patients with an implantable cardioverter defibrillator.

Authors:  Pil Sang Song; June Soo Kim; Dae-Hee Shin; Jung Wae Park; Ki In Bae; Chang Hee Lee; Dong Chae Jung; Dong Ryeol Ryu; Young Keun On
Journal:  Yonsei Med J       Date:  2011-01       Impact factor: 2.759

4.  Infarct tissue characterization in implantable cardioverter-defibrillator recipients for primary versus secondary prevention following myocardial infarction: a study with contrast-enhancement cardiovascular magnetic resonance imaging.

Authors:  Marlon A G M Olimulder; Karin Kraaier; Michel A Galjee; Marcoen F Scholten; Jan van Es; Lodewijk J Wagenaar; Job van der Palen; Clemens von Birgelen
Journal:  Int J Cardiovasc Imaging       Date:  2012-06-09       Impact factor: 2.357

5.  Cycle length of nonsustanied ventricular tachycardias among ICD patients: implications on subsequent appropriate therapies.

Authors:  Javier Jiménez-Candil; Olga Duran; Armando Oterino; Jendri Pérez; Juan Carlos Castro; Jesús Hernández; José Moríñigo; Manuel Sánchez García; Pedro L Sánchez
Journal:  BMC Cardiovasc Disord       Date:  2021-05-31       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.